Patent intelligence · US
US 8445461
Pharmaceutical composition for meniere's disease
Pharmaceutical composition for meniere's disease
Patent details — US 8445461
- Jurisdiction
- US
- Status
- granted
- Grant date
- May 21, 2013
- Expiration
- May 16, 2033
- Applicant
- Setsuko Takeda
- Claims
- 14
- CPC classes
- A61K, A61K31/047, A61K31/702, A61K31/715
Quick answer
US 8445461 (Pharmaceutical composition for meniere's disease) is held by Setsuko Takeda. Status: granted. Granted May 21, 2013. Expires May 16, 2033 (7 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Setsuko Takeda
- Grant date
- Expiration
- Claims
- 14
- CPC classes
- A61K, A61K31/047, A61K31/702, A61K31/715, A61K31/717, A61K31/723
More from Setsuko Takeda
Related pharmaceutical patents in our USPTO index.
-
US 12428403
N-(heterocyclyl and heterocyclylalkyl)-3-benzylpyridin-2-amine derivatives as SSTR4 agonists
granted -
US 12421188
Heterocyclic compound and use thereof
granted -
US 12419890
Administration of sumo-activating enzyme inhibitor and checkpoint inhibitors
granted -
US 12415866
Monoclonal antibody inhibitor of Factor XIIa
granted -
US 12415782
Heterocyclic compound and use thereof
granted -
US 12409210
CNS delivery of therapeutic agents
granted -
US 12404237
Method of treating excessive sleepiness and/or cataplexy using n-{2-(([1,1′-biphenyl]-3-yl)methyl)pyrrolidin-3-yl}sulfonamide derivatives
granted -
US 12403154
Administration of sting agonist and checkpoint inhibitors
granted
Frequently asked questions
What is US patent 8445461?
US 8445461 (Pharmaceutical composition for meniere's disease) is held by Setsuko Takeda. Status: granted. Granted May 21, 2013. Expires May 16, 2033 (7 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 8445461?
Setsuko Takeda is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 1,436 pharmaceutical patents for this assignee.
When does US 8445461 expire?
Our index shows an expiration date of May 16, 2033 (7 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.